Human Wharton’s jelly mesenchymal stem cells inhibit cytokine storm in acute respiratory distress syndrome in a rat model

• Published in: Asian Pacific Journal of Tropical Biomedicine
• Main Authors: Wahyu Widowati, Teresa Liliana Wargasetia, Fanny Rahardja, Rimonta F Gunanegara, Didik Priyandoko, Marisca Evalina Gondokesumo, Ervi Afifah, Cahyaning Riski Wijayanti, Rizal Rizal
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wolters Kluwer Medknow Publications 2022
• Subjects: human wharton’s jelly mesenchymal stem cells; acute respiratory distress syndrome; tnf-α; il-18; nf-κb; inflammatory marker; Arctic medicine. Tropical medicine; RC955-962; Biology (General); QH301-705.5; Arctic
• Online Access: https://doi.org/10.4103/2221-1691.350182; https://doaj.org/article/a391bb4c47284ff8bc34e5366551c191

Objective: To evaluate the potential effect of human Wharton’s jelly mesenchymal stem cells (hWJMSCs) on acute respiratory distress syndrome in lipopolysaccharide (LPS)-induced rats. Methods: The hWJMSCs (5×104/mL, 5×105/mL, 5×106/mL) were administered to rats on day 1 and day 8 after being induced by LPS (5 mg/kg body weight). TNF-α levels in the lung and IL- 18 and IL-1β levels in the serum were measured using ELISA. In addition, caspase-1 expression in lung tissues was quantified using qRT-PCR, and NF-κB and IL-6 expressions were assessed using immunohistochemistry. Results: The hWJMSCs decreased TNF-α levels in the lung and plasma IL-18 and IL-1β levels. Moreover, the hWJMSCs downregulated the expressions of caspase-1, IL-6, and NF-κB in lung tissues. Conclusions: The hWJMSCs can decrease inflammatory markers of acute respiratory distress syndrome in a rat model and may be further investigated for the treatment of acute respiratory distress syndrome.